Across the US, the UK, and parts of Europe, CGT progress is being held back by an inability to secure starting material ...

The late-stage MonumenTAL-3 trial of Talvey (talquetamab), given in combination with J&J and Genmab's anti-CD38 antibody ...

Men with a particular form of prostate cancer now have a targeted treatment for the first time, thanks to FDA approval of a ...

Sanofi's neurology pipeline has had a hole blown in it after a phase 3 trial of riliprubart (SAR445088) in rare disease ...

Novo Nordisk has become the latest pharma group to be targeted by a cyberattack, with the company revealing that some patient ...

Incyte has agreed to buy Star Therapeutics subsidiary Vega Therapeutics for $1.25 billion upfront, adding a late-stage drug ...

In a paper published in the journal Lingua, researchers at the University of Surrey polled 300 patients who used a chatbot ...

There are around 46,000 new cases of prostate cancer each year in England and Wales, with 13% of these cases showing signs of ...

AI company Anthropic has launched a new large language model (LLM) – Claude Fable 5 – claiming its capabilities as a tool for ...

San Francisco-based SonoThera closed an oversubscribed $125 million Series B financing round, saying it will use the proceeds ...

Zasocitinib – which is billed by Takeda as a second-generation TYK2 inhibitor – was more effective than Sotyktu ...

AbbVie's Aquipta can now be commissioned by the NHS in England and Wales as an acute treatment for migraine, adding to its ...